Dengke Bao | Tumor biology | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Dengke Bao | Tumor biology | Best Researcher Award 

Dengke Bao, Ph.D., is a professor, Ph.D. supervisor, and Deputy Dean at the School of Pharmacy, Henan University. He is a recipient of the Excellent Youth Fund Project of the Henan Natural Science Foundation and the 2022 China Postdoctoral Science Foundation Funding. His research focuses on mitochondria-related mechanisms in tumorigenesis, cancer progression, and immune regulation. He has published 20+ SCI-indexed papers in top journals like Oncogene and Cell Death & Disease and serves as an editorial member for Scientific Reports. His work provides new insights into tumor microenvironment remodeling and drug resistance in cancer therapy.

Prof. Dr. Dengke Bao | Henan University | China

Profile

SCOPUS ID

ORCID ID

🎓Education

  • Dengke Bao holds a Ph.D. and has established himself as a distinguished professor and Ph.D. supervisor. His academic journey has been marked by excellence, leading to his recognition as a Program for Central Plains Youth Top Talent and a recipient of multiple prestigious research grants.

👨‍🏫Experience

  • Currently serving as the Deputy Dean of the School of Pharmacy at Henan University, Dengke Bao has played a pivotal role in advancing molecular diagnostics and therapy. He is also the Deputy Director of the Henan Engineering Research Center for Molecular Diagnosis and Therapy of Esophageal Cancer and the Director of the Laboratory of Biomarkers and Liquid Biopsy in Kaifeng. His work has significantly contributed to understanding mitochondria-related mechanisms in tumorigenesis, cancer progression, and tumor immune regulation.

🏆Awards and Recognitions

  • Dengke Bao has been honored with numerous awards, including the Excellent Youth Fund Project of the Henan Natural Science Foundation and recognition as a Young Core Instructor of Henan. He was also a recipient of the 2022 China Postdoctoral Science Foundation Funding, highlighting his exceptional contributions to the field of oncology research.

💡Skills and Certifications

  • With a deep expertise in tumor biology and the tumor microenvironment, Dengke Bao specializes in investigating mitochondrial damage-associated molecular patterns (DAMPs) and their role in inflammatory responses and cancer therapy resistance. His research combines molecular biology, oncology, and immunology to uncover new therapeutic strategies for hepatocellular carcinoma (HCC) and other malignancies.

🔬 Research Focus

  • Dengke Bao’s research is centered on understanding how mitochondrial damage-associated molecular patterns influence the tumor microenvironment and immune regulation. His groundbreaking study demonstrated that sorafenib treatment in HCC induces the release of mitochondrial DNA into the tumor microenvironment, promoting M2 macrophage polarization through TLR9 activation and enhancing sorafenib resistance. His findings offer a new perspective on targeting mitochondrial DAMPs to reprogram tumor-associated macrophages, providing novel strategies to improve therapeutic efficacy and overcome drug resistance in cancer treatment.

 📚 Publications and Editorial Roles

  • Dengke Bao has authored over 20 SCI-indexed papers as a first or corresponding author in high-impact journals, including Oncogene, Journal of Experimental & Clinical Cancer Research, and Cell Death & Disease. He also serves as an editorial member for Scientific Reports, further solidifying his influence in the field of cancer research.

🌎Conclusion

  • Given his exceptional research contributions, leadership, and impact in oncology, Dengke Bao is a highly suitable nominee for the Research for Best Researcher Award. His work is not only innovative but also holds great promise for improving cancer treatment and patient outcomes, making him a deserving recipient of this prestigious recognition.

📖Publications

  • TEFM facilitates uterine corpus endometrial carcinoma progression by activating ROS-NFκB pathway

    • Authors: J. Lei, Q. Zhu, J. Guo, D. Bao, R. Guo
    • Journal: Journal of Translational Medicine, 2024

  • Tenofovir disoproxil fumarate mediates neuronal injury by inducing neurotoxicity

    • Authors: X. Yang, J. Zhang, Y. Cheng, H. Liu, D. Bao
    • Journal: European Journal of Clinical Microbiology and Infectious Diseases, 2023

  • PRRSV infection activates NLRP3 inflammasome through inducing cytosolic mitochondrial DNA stress

    • Authors: H. Li, X. Yang, Y. Song, B. Wan, D. Bao
    • Journal: Veterinary Microbiology, 2023

Shan Su | Oncology | Best Researcher Award

Posted on by sciencefather

Dr. Shan Su | Oncology | Best Researcher Award

Professional Memberships:

  • Her membership with the International Association for the Study of Lung Cancer (IASLC) indicates her active participation in the global oncology research community, further enhancing her profile as a top researcher.
Dr. Shan Su ,Guangzhou Chest Hospital, China

Profile

Scopus

OrcID

🌱EARLY ACADEMIC PURSUITS

  • Shan Su began her academic journey with a strong focus on clinical oncology, immersing herself in the study of treatment methodologies and therapies for various types of cancer, especially lung cancer. Early in her career, her dedication to patient-centered treatment approaches led her to explore a range of therapeutic practices, including chemotherapy, targeted therapies, and immunotherapy.

💼 PROFESSIONAL ENDEAVORS

  • As the Chief Physician at Guangzhou Chest Hospital, Shan Su has taken on a prominent role in the field of oncology, specializing in advanced and innovative cancer treatments. Over her ten-year tenure, she has applied targeted therapy, immunotherapy, and even local microwave ablation to treat malignant tumors, focusing particularly on lung tumors. Her role involves not only treating patients but also leading clinical advancements and educating the next generation of oncology professionals.

🔬CONTRIBUTIONS AND RESEARCH FOCUS 

  • Dr. Su’s research has paved the way in studying complex interactions between malignancies and other diseases, notably tuberculosis (TB). Recognizing a gap in the understanding of cancer patients with concurrent TB, she led a pioneering cohort study—the largest of its kind worldwide—documenting unique treatment challenges and outcomes. Currently, she is spearheading the first international clinical study investigating the effects of combining first-line chemotherapy with immunotherapy for lung cancer patients who have active pulmonary TB, with a primary focus on evaluating the safety and efficacy of these combined treatments.

📚ACADEMIC CITES 

  • Throughout her career, Dr. Su’s research has been recognized and cited by numerous peers in the medical community, underscoring her contributions to oncology and her influence on cancer research. Her work in combining immunotherapy with chemotherapy for complex cases is particularly well-regarded, with citations reflecting the growing interest and importance of her findings.

🌍IMPACT AND INFLUENCE

  • Dr. Su’s work has influenced clinical practices on a global scale. Her expertise has contributed significantly to the understanding of complex cases involving co-occurring cancer and TB, impacting treatment protocols and inspiring other researchers to explore similar areas. As a member of the International Association for the Study of Lung Cancer (IASLC), she collaborates with a network of global oncology professionals to advance knowledge and share insights into lung cancer treatment.

🌟LEGACY AND FUTURE AND CONTRIBUTIONS

  • Looking forward, Dr. Su remains committed to advancing oncological treatments, especially for complex cases like cancer with tuberculosis. Her ongoing research projects hold great promise for improving patient outcomes and expanding treatment options, making her a pioneer in her field. Dr. Su’s legacy will likely include groundbreaking contributions to cancer therapy innovations, laying the foundation for future treatments and offering hope for patients worldwide.

📄Publications

  • The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study
    Authors: Li, L., Zhang, H., Xie, Y., Cen, W., Koundal, D.
    Journal: Computational and Mathematical Methods in Medicine, 2022, 2022, 1475871
  • Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage
    Authors: Su, S., Ye, M.-F., Cai, X.-T., Huang, H.-Y., Dong, Z.-Y.
    Journal: BMC Medicine, 2021, 19(1), 322
  • Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival
    Authors: Chen, R.-L., Zhou, J.-X., Cao, Y., Wang, S.-Y., Lin, L.-Z.
    Journal: Frontiers in Immunology, 2020, 11, 1933
  • Tumor Mutational Burden and Genomic Alterations in Chinese Small Cell Lung Cancer Measured by Whole-Exome Sequencing
    Authors: Su, S., Zou, J.-J., Zeng, Y.-Y., Zhao, Z.-G., Liu, J.-X.
    Journal: BioMed Research International, 2019, 2019, 6096350
  • Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy
    Authors: Zou, J., Su, S., Chen, Z., Xia, Y., Huang, D.
    Journal: Artificial Cells, Nanomedicine and Biotechnology, 2019, 47(1), pp. 3456–3464

Lina Wang | Oncology | Best Researcher Award

Posted on by sciencefather

Assoc Prof Dr.Lina Wang | Oncology | Best Researcher Award

Grant Funding:
  •  Dr. Wang has been the recipient of competitive research funding from the National Natural Science Foundation of China, which further underscores her research capabilities and the recognition of her work at the national level.
Assoc Prof Dr. Lina Wang, Affiliated Hospital of Jining Medical University, China

Profile

Scopus

OrcID

🏛️Early Academic Pursuits

  • Lina Wang completed her Bachelor’s degree at Taishan Medical University (2004-2010), followed by a Master’s degree from Peking Union Medical College (2010-2013). She further pursued her Ph.D. in Medicine at Shanghai Jiao Tong University School of Medicine (2013-2017). With an unrelenting drive for excellence, she completed a postdoctoral fellowship at the University of Maryland School of Medicine (2018-2020), where she deepened her understanding of oncological research and built a strong foundation for her future studies.

👨‍🔬 PROFESSIONAL ENDEAVORS

  • Since July 2017, Lina Wang has been serving as an Associate Professor at the Affiliated Hospital of Jining Medical University. Her professional journey has been marked by significant strides in cancer research, particularly focusing on lung cancer, esophageal cancer, and leukemia. She is committed to advancing cancer diagnosis, treatment, and prognosis through rigorous scientific investigation. Her postdoctoral research at the University of Maryland significantly enhanced her expertise in molecular oncology.

🏆 CONTRIBUTIONS AND RESEARCH FOCUS

  • Lina Wang’s research has brought significant advancements in the understanding of cancer pathogenesis, particularly in lung and esophageal cancers. Her work in developing efficient prognostic models based on cuproptosis and disulfidptosis has established her as a leader in the field of cancer biomarkers. She has extensively explored the molecular mechanisms underlying tumor progression and has validated several diagnostic and prognostic biomarkers for lung adenocarcinoma. Notably, her research on the TGF-β1/SH2B3 axis has provided new insights into the regulation of anoikis resistance and epithelial-mesenchymal transition (EMT) in lung cancer cells. Additionally, her earlier studies demonstrated that the deletion of Stk40 impairs definitive erythropoiesis in mouse fetal livers, contributing to the broader understanding of developmental biology.

📊 IMPACT AND INFLUENCE

  • Lina Wang’s groundbreaking research has not only advanced scientific knowledge but also holds potential to transform clinical practices in cancer diagnosis and treatment. By identifying tumor-associated diagnostic and prognostic markers, her work offers tangible benefits to clinical patients, improving the precision of medical interventions. Her research on the molecular mechanisms driving cancer progression contributes to the development of targeted therapies that can effectively treat aggressive cancers such as lung adenocarcinoma.

💰GRANTS AND FUNDING

  • Lina Wang’s research efforts have been recognized by the National Natural Science Foundation of China, which awarded her a grant (grant no. 81800182) for her project from 2019 to 2021. This funding has enabled her to push the boundaries of cancer research, supporting her work on diagnostic and prognostic markers, as well as molecular mechanisms in oncology.

🏅ACADEMIC CITES

  • Lina Wang’s publications on topics such as cuproptosis and cancer prognosis have been widely cited in scientific literature, reflecting the relevance and influence of her work in the academic community. Her research has contributed to the establishment of new prognostic models, and her findings have been cited in numerous oncology-focused journals, further solidifying her reputation as a key contributor in cancer research.

🚀LEGACY AND FUTURE CONTRIBUTIONS

  • As Lina Wang continues her academic journey, her future contributions promise to further enhance the understanding of cancer mechanisms and improve treatment strategies. With a focus on the identification of novel biomarkers and therapeutic targets, her work is expected to have a lasting impact on the fields of oncology and personalized medicine. Her ongoing research efforts are set to leave a lasting legacy in the medical community, inspiring future generations of researchers.

📄Publications

  •  Construction of lncRNA Prognostic Model Related to Disulfidptosis in Lung Adenocarcinoma
    Authors: Zhang, L., Wang, S., Wang, L.
    Journal: Heliyon, 2024, 10(15), e35657
  •  Prognostic Value and Immunological Function of Cuproptosis-Related Genes in Lung Adenocarcinoma
    Authors: Zhang, L., Wang, S., Wang, L.
    Journal: Heliyon, 2024, 10(9), e30446
  • LncRNA CALML3-AS1 Modulated by m6A Modification Induces BTNL9 Methylation to Drive Non-Small-Cell Lung Cancer Progression
    Authors: Zhang, H., Wang, S.-Q., Zhu, J.-B., Duan, C.-J., Zhang, C.-F.
    Journal: Cancer Gene Therapy, 2023, 30(12), pp. 1649–1662
  •  Research Progress on Ferroptosis in Lung Cancer 
    Authors: Dong, Z., Wang, L., Zhang, L., Hu, R.
    Journal: Journal of Chinese Physician, 2023, 25(11), pp. 1754–1757
  •  Alterations of Gut Microbiota and Gut Metabolites in the Young-Adult Vitiligo Patients
    Authors: Wu, Q., Cheng, P., Shao, T., Yao, S., Lu, B.
    Journal: Journal of the European Academy of Dermatology and Venereology, 2023, 37(7), pp. e904–e907